Treating neuropathic pain and comorbid affective disorders: Preclinical and clinical evidence.
affective disorders
anxiety
depression
neuropathic pain
treatment
Journal
Pain practice : the official journal of World Institute of Pain
ISSN: 1533-2500
Titre abrégé: Pain Pract
Pays: United States
ID NLM: 101130835
Informations de publication
Date de publication:
04 Apr 2024
04 Apr 2024
Historique:
medline:
4
4
2024
pubmed:
4
4
2024
entrez:
4
4
2024
Statut:
aheadofprint
Résumé
Neuropathic pain (NP) significantly impacts quality of life and often coexists with affective disorders such as anxiety and depression. Addressing both NP and its psychiatric manifestations requires a comprehensive understanding of therapeutic options. This study aimed to review the main pharmacological and non-pharmacological treatments for NP and comorbid affective disorders to describe their mechanisms of action and how they are commonly used in clinical practice. A review was conducted across five electronic databases, focusing on pharmacological and non-pharmacological treatments for NP and its associated affective disorders. The following combination of Mesh and title/abstract keywords were used: "neuropathic pain," "affective disorders," "depression," "anxiety," "treatment," and "therapy." Both animal and human studies were included to discuss the underlying therapeutic mechanisms of these interventions. Pharmacological interventions, including antidepressants, anticonvulsants, and opioids, modulate neural synaptic transmission to alleviate NP. Topical agents, such as capsaicin, lidocaine patches, and botulinum toxin A, offer localized relief by desensitizing pain pathways. Some of these drugs, especially antidepressants, also treat comorbid affective disorders. Non-pharmacological techniques, including repetitive transcranial magnetic stimulation, transcranial direct current stimulation, and photobiomodulation therapy, modulate cortical activity and have shown promise for NP and mood disorders. The interconnection between NP and comorbid affective disorders necessitates holistic therapeutic strategies. Some pharmacological treatments can be used for both conditions, and non-pharmacological interventions have emerged as promising complementary approaches. Future research should explore novel molecular pathways to enhance treatment options for these interrelated conditions.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : 2019/21158-8
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : 2021/10982-1
Informations de copyright
© 2024 World Institute of Pain.
Références
Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976–1982.
Nicholas M, Vlaeyen JWS, Rief W, Barke A, Aziz Q, Benoliel R, et al. The IASP classification of chronic pain for ICD‐11: chronic primary pain. Pain. 2019;160(1):28–37.
Murnion BP. Neuropathic pain: current definition and review of drug treatment. Aust Prescr. 2018;41(3):60–63.
van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155(4):654–662.
Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. The neuropathic pain: an overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol. 2019;33:2058738419838383.
Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002.
Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol. 2014;13(9):924–935.
Cherif F, Zouari HG, Cherif W, Hadded M, Cheour M, Damak R. Depression prevalence in neuropathic pain and its impact on the quality of life. Pain Res Manag. 2020;2020:7408508.
Edwards RR, Dworkin RH, Sullivan MD, Turk DC, Wasan AD. The role of psychosocial processes in the development and maintenance of chronic pain. J Pain. 2016;17(9 Suppl):T70–T92.
Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33(1):87–107.
Mosconi T, Kruger L. Fixed‐diameter polyethylene cuffs applied to the rat sciatic nerve induce a painful neuropathy: ultrastructural morphometric analysis of axonal alterations. Pain. 1996;64(1):37–57.
Ho Kim S, Mo Chung J. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 1992;50(3):355–363.
Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain. 1990;43(2):205–218.
Lenzen S. The mechanisms of alloxan‐ and streptozotocin‐induced diabetes. Diabetologia. 2008;51(2):216–226.
Barrot M. Tests and models of nociception and pain in rodents. Neuroscience. 2012;211:39–50.
O'Callaghan JP, Holtzman SG. Quantification of the analgesic activity of narcotic antagonists by a modified hot‐plate procedure. J Pharmacol Exp Ther. 1975;192(3):497–505.
Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus‐maze as a measure of anxiety in the rat. J Neurosci Methods. 1985;14(3):149–167.
Hasnie FS, Breuer J, Parker S, Wallace V, Blackbeard J, Lever I, et al. Further characterization of a rat model of varicella zoster virus‐associated pain: relationship between mechanical hypersensitivity and anxiety‐related behavior, and the influence of analgesic drugs. Neuroscience. 2007;144(4):1495–1508.
Choleris E, Thomas AW, Kavaliers M, Prato FS. A detailed ethological analysis of the mouse open field test: effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field. Neurosci Biobehav Rev. 2001;25(3):235–260.
Crawley J, Goodwin FK. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav. 1980;13(2):167–170.
Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977;266(5604):730–732.
Katz RJ. Animal model of depression: pharmacological sensitivity of a hedonic deficit. Pharmacol Biochem Behav. 1982;16(6):965–968.
Moraczewski J, Awosika AO, Aedma KK. Tricyclic antidepressants. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK557791/
Lambert O, Bourin M. SNRIs: mechanism of action and clinical features. Expert Rev Neurother. 2002;2(6):849–858.
Benbouzid M, Choucair‐Jaafar N, Yalcin I, Waltisperger E, Muller A, Freund‐Mercier MJ, et al. Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffing in mice. Eur J Pain. 2008;12(8):1008–1017.
Ito S, Suto T, Saito S, Obata H. Repeated administration of duloxetine suppresses neuropathic pain by accumulating effects of noradrenaline in the spinal cord. Anesth Analg. 2018;126(1):298–307.
Hughes S, Hickey L, Donaldson LF, Lumb BM, Pickering AE. Intrathecal reboxetine suppresses evoked and ongoing neuropathic pain behaviours by restoring spinal noradrenergic inhibitory tone. Pain. 2015;156(2):328–334.
Li D, Lee JH, Choi CW, Kim J, Kim SK, Kim W. The analgesic effect of venlafaxine and its mechanism on oxaliplatin‐induced neuropathic pain in mice. Int J Mol Sci. 2019;20(7):1652.
Hayashida KI, Obata H. Strategies to treat chronic pain and strengthen impaired descending noradrenergic inhibitory system. Int J Mol Sci. 2019;20(4):822.
Bahari Z, Meftahi GH. Spinal α2‐adrenoceptors and neuropathic pain modulation; therapeutic target. Br J Pharmacol. 2019;176(14):2366–2381.
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta‐analysis. Lancet Neurol. 2015;14(2):162–173.
Jesse CR, Wilhelm EA, Nogueira CW. Depression‐like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion. Psychopharmacology. 2010;212(4):513–522.
Matsuzawa‐Yanagida K, Narita M, Nakajima M, Kuzumaki N, Niikura K, Nozaki H, et al. Usefulness of antidepressants for improving the neuropathic pain‐like state and pain‐induced anxiety through actions at different brain sites. Neuropsychopharmacology. 2008;33(8):1952–1965.
Gebhardt S, Heinzel‐Gutenbrunner M, König U. Pain relief in depressive disorders: A meta‐analysis of the effects of antidepressants. J Clin Psychopharmacol. 2016;36(6):658–668.
Shelton RC. Serotonin and norepinephrine reuptake inhibitors. Handb Exp Pharmacol. 2019;250:145–180.
Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. Drugs. 2008;68(18):2611–2632.
Caruso R, Ostuzzi G, Turrini G, Ballette F, Recla E, Dall'Olio R, et al. Beyond pain: can antidepressants improve depressive symptoms and quality of life in patients with neuropathic pain? A systematic review and meta‐analysis. Pain. 2019;160(10):2186–2198.
Kolacz M, Kosson D, Puchalska‐Kowalczyk E, Mikaszewska‐Sokolewicz M, Lisowska B, Malec‐Milewska M. Analysis of antidepressant, benzodiazepine anxiolytic, and hypnotic use when treating depression, anxiety, and aggression in pain clinic patients treated for neuropathic pain. Life (Basel). 2022;12(3):433.
Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163(20):2433–2445.
Kerr GW, McGuffie AC, Wilkie S. Tricyclic antidepressant overdose: a review. Emerg Med J. 2001;18(4):236–241.
Kumar BV, Connors TJ, Farber DL. Human T cell development, localization, and function throughout life. Immunity. 2018;48(2):202–213.
Surcheva S, Todorova L, Maslarov D, Vlaskovska M. Preclinic and clinic effectiveness of gabapentin and pregabalin for treatment of neuropathic pain in rats and diabetic patients. Biotechnol Biotechnol Equip. 2017;31(3):568–573.
Patel R, Dickenson AH. Mechanisms of the gabapentinoids and α 2 δ‐1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect. 2016;4(2):e00205.
D'Arco M, Margas W, Cassidy JS, Dolphin AC. The upregulation of α2δ‐1 subunit modulates activity‐dependent Ca2+ signals in sensory neurons. J Neurosci. 2015;35(15):5891–5903.
Parsons B, Fujii K, Nozawa K, Yoshiyama T, Ortiz M, Whalen E. The efficacy of pregabalin for the treatment of neuropathic pain in Japanese subjects with moderate or severe baseline pain. J Pain Res. 2019;12:1061–1068.
Serpell MG, Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndromes: a randomised, double‐blind, placebo‐controlled trial. Pain. 2002;99(3):557–566.
Davari M, Amani B, Amani B, Khanijahani A, Akbarzadeh A, Shabestan R. Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta‐analysis. Korean J Pain. 2020;33(1):3–12.
Roeska K, Doods H, Arndt K, Treede RD, Ceci A. Anxiety‐like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin. Pain. 2008;139(2):349–357.
Grégoire S, Michaud V, Chapuy E, Eschalier A, Ardid D. Study of emotional and cognitive impairments in mononeuropathic rats: effect of duloxetine and gabapentin. Pain. 2012;153(8):1657–1663.
Sałat K, Gdula‐Argasińska J, Malikowska N, Podkowa A, Lipkowska A, Librowski T. Effect of pregabalin on contextual memory deficits and inflammatory state‐related protein expression in streptozotocin‐induced diabetic mice. Naunyn Schmiedeberg's Arch Pharmacol. 2016;389(6):613–623.
La Porta C, Lara‐Mayorga IM, Negrete R, Maldonado R. Effects of pregabalin on the nociceptive, emotional and cognitive manifestations of neuropathic pain in mice. Eur J Pain. 2016;20(9):1454–1466.
Nemeroff CB. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull. 2003;37(4):133–146.
Fu B, Wen SN, Wang B, Wang K, Zhang JY, Weng XC, et al. Gabapentin regulates dopaminergic neuron firing and theta oscillation in the ventral tegmental area to reverse depression‐like behavior in chronic neuropathic pain state. J Pain Res. 2018;11:2247–2256.
Yu X, Liu T, Zhao D, Yang K, Zhang X, Zhang M, et al. Efficacy and safety of Pregabalin in neuropathic pain followed spinal cord injury: A review and meta‐analysis of randomized controlled trials. Clin J Pain. 2019;35(3):272–278.
Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double‐blind, placebo‐controlled trial. Pain. 2004;110(3):628–638.
Bestard JA, Toth CC. An open‐label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract. 2011;11(4):353–368.
Mehta S, McIntyre A, Dijkers M, Loh E, Teasell RW. Gabapentinoids are effective in decreasing neuropathic pain and other secondary outcomes after spinal cord injury: a meta‐analysis. Arch Phys Med Rehabil. 2014;95(11):2180–2186.
Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661–669.
Haanpää M, Treede RD. Capsaicin for neuropathic pain: linking traditional medicine and molecular biology. Eur Neurol. 2012;68(5):264–275.
Wang S, Bian C, Yang J, Arora V, Gao Y, Wei F, et al. Ablation of TRPV1+ afferent terminals by capsaicin mediates long‐lasting analgesia for trigeminal neuropathic pain. eNeuro. 2020;7(3):ENEURO.0118‐20.2020.
Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P Jr, Rauck R, et al. NGX‐4010, a high‐concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double‐blind study. Lancet Neurol. 2008;7(12):1106–1112.
Simpson DM, Estanislao L, Brown SJ, Sampson J. An open‐label pilot study of high‐concentration capsaicin patch in painful HIV neuropathy. J Pain Symptom Manag. 2008;35(3):299–306.
Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;1(1):CD007393.
Casale R. Capsaicin 179‐mg cutaneous patch in the treatment of post‐surgical neuropathic pain: a scoping review of current evidence and place in therapy. Expert Rev Neurother. 2021;21(10):1147–1158.
Sultana A, Singla RK, He X, Sun Y, Alam MS, Shen B. Topical capsaicin for the treatment of neuropathic pain. Curr Drug Metab. 2021;22(3):198–207.
van Nooten F, Treur M, Pantiri K, Stoker M, Charokopou M. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta‐analysis. Clin Ther. 2017;39(4):787–803.e18.
Hennies HH, Friderichs E, Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988;38(7):877–880.
Dagilgan S, Erdogan S, Aksu F. Tramadol reverses the effects of neuropathic pain on oocyte maturation and copulation ratio in mice. Eurasian J Med. 2018;50(3):182–186.
Corona‐Ramos JN, De la O‐Arciniega M, Déciga‐Campos M, Medina‐López JR, Domínguez‐Ramírez AM, Jaramillo‐Morales OA, et al. The Antinociceptive effects of tramadol and/or gabapentin on rat neuropathic pain induced by a chronic constriction injury. Drug Dev Res. 2016;77(5):217–226.
Alvarez P, Brun A, Labertrandie A, Lopez J, Correa A, Constandil L, et al. Antihyperalgesic effects of clomipramine and tramadol in a model of posttraumatic trigeminal neuropathic pain in mice. J Orofac Pain. 2011;25(4):354–363.
Kaneko K, Umehara M, Homan T, Okamoto K, Oka M, Oyama T. The analgesic effect of tramadol in animal models of neuropathic pain and fibromyalgia. Neurosci Lett. 2014;562:28–33.
Berrocoso E, De Benito MD, Mico JA. Role of serotonin 5‐HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats. Psychopharmacology. 2007;193(1):97–105.
Caspani O, Reitz MC, Ceci A, Kremer A, Treede RD. Tramadol reduces anxiety‐related and depression‐associated behaviors presumably induced by pain in the chronic constriction injury model of neuropathic pain in rats. Pharmacol Biochem Behav. 2014;124:290–296.
Barber J. Examining the use of tramadol hydrochloride as an antidepressant. Exp Clin Psychopharmacol. 2011;19(2):123–130.
Duehmke RM, Derry S, Wiffen PJ, Bell RF, Aldington D, Moore RA. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD003726.
Tian J, Gu Y, Su D, Wu Y, Wang X. Effects of intrathecal lidocaine on hyperalgesia and allodynia following chronic constriction injury in rats. Eur J Pain. 2009;13(2):130–137.
Zheng Y, Hou X, Yang S. Lidocaine potentiates SOCS3 to attenuate inflammation in microglia and suppress neuropathic pain. Cell Mol Neurobiol. 2019;39:1081–1092.
Suzuki N, Hasegawa‐Moriyama M, Takahashi Y, Kamikubo Y, Sakurai T, Inada E. Lidocaine attenuates the development of diabetic‐induced tactile allodynia by inhibiting microglial activation. Anesth Analg. 2011;113(4):941–946.
Song T, Gu K, Wang W, Wang H, Yang Y, Yang L, et al. Prolonged suppression of neuropathic pain by sequential delivery of lidocaine and thalidomide drugs using PEGylated graphene oxide. J Pharm Sci. 2015;104(11):3851–3860.
Werdehausen R, Mittnacht S, Bee LA, Minett MS, Armbruster A, Bauer I, et al. The lidocaine metabolite N‐ethylglycine has antinociceptive effects in experimental inflammatory and neuropathic pain. Pain. 2015;156(9):1647–1659.
Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;2014(7):CD010958.
Silvinato A, Floriano I, Bernardo WM. Multiple lidocaine infusions for relief of neuropathic pain: systematic review and meta‐analysis. Rev Assoc Med Bras (1992). 2020;66(5):583–588.
Zhu B, Zhou X, Zhou Q, Wang H, Wang S, Luo K. Intra‐venous lidocaine to relieve neuropathic pain: a systematic review and meta‐analysis. Front Neurol. 2019;10:954.
Liu H, Lu F, Zhou D, Yin Y, Li J, Yang BX, et al. The analgesic and emotional response to intravenous lidocaine infusion in the treatment of Postherpetic neuralgia: a randomized, double‐blinded, placebo‐controlled study. Clin J Pain. 2018;34(11):1025–1031.
Smith HS. Opioids and neuropathic pain. Pain Physician. 2012;15(3 Suppl):ES93–ES110.
Ordóñez Gallego A, González Barón M, Espinosa Arranz E. Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007;9(5):298–307.
Yang PP, Yeh GC, Huang EYK, Law PY, Loh HH, Tao PL. Effects of dextromethorphan and oxycodone on treatment of neuropathic pain in mice. J Biomed Sci. 2015;22(1):81.
Thibault K, Calvino B, Rivals I, Marchand F, Dubacq S, McMahon SB, et al. Molecular mechanisms underlying the enhanced analgesic effect of oxycodone compared to morphine in chemotherapy‐induced neuropathic pain. PLoS One. 2014;9(3):e91297.
Berrios I, Castro C, Kuffler DP. Morphine: axon regeneration, neuroprotection, neurotoxicity, tolerance, and neuropathic pain. P R Health Sci J. 2008;27(2):119–128.
Leite Junior JB, de Mello Bastos JM, Samuels RI, Carey RJ, Carrera MP. Reversal of morphine conditioned behavior by an anti‐dopaminergic post‐trial drug treatment during re‐consolidation. Behav Brain Res. 2019;359:771–782.
Kazantzis NP, Casey SL, Seow PW, Mitchell VA, Vaughan CW. Opioid and cannabinoid synergy in a mouse neuropathic pain model. Br J Pharmacol. 2016;173(16):2521–2531.
Leitl MD, Negus SS. Pharmacological modulation of neuropathic pain‐related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9‐tetrahydrocannabinol on formalin‐induced depression of intracranial self‐stimulation in rats. Behav Pharmacol. 2016;27(4):364–376.
Wallace VCJ, Segerdahl AR, Blackbeard J, Pheby T, Rice ASC. Anxiety‐like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti‐retroviral‐associated neuropathic pain. Neurosci Lett. 2008;448(1–9):153–156.
Gimbel JS, Richards P, Portenoy RK. Controlled‐release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003;60(6):927–934.
Watson CPN, Moulin D, Watt‐Watson J, Gordon A, Eisenhoffer J. Controlled‐release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105(1–2):71–78.
Sommer C, Klose P, Welsch P, Petzke F, Häuser W. Opioids for chronic non‐cancer neuropathic pain. An updated systematic review and meta‐analysis of efficacy, tolerability and safety in randomized placebo‐controlled studies of at least 4 weeks duration. Eur J Pain. 2020;24(1):3–18.
Cooper TE, Chen J, Wiffen PJ, Derry S, Carr DB, Aldington D, et al. Morphine for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;2017(5):CD011669.
Marinelli S, Luvisetto S, Cobianchi S, Makuch W, Obara I, Mezzaroma E, et al. Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience. 2010;171(1):316–328.
Luvisetto S, Marinelli S, Cobianchi S, Pavone F. Anti‐allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience. 2007;145(1):1–4.
Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW, Johnson E, et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem. 2003;278(2):1363–1371.
McMahon HT, Foran P, Dolly JO, Verhage M, Wiegant VM, Nicholls DG. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma‐aminobutyric acid, aspartate, and met‐enkephalin release from synaptosomes. Clues to the locus of action. J Biol Chem. 1992;267(30):21338–21343.
Hou YP, Zhang YP, Song YF, Zhu CM, Wang YC, Xie GL. Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo. Can J Physiol Pharmacol. 2007;85(2):209–214.
Durham PL, Cady R, Cady R. Regulation of calcitonin gene‐related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44(1):35–42; discussion 42–43.
Chen WJ, Niu JQ, Chen YT, Deng WJ, Xu YY, Liu J, et al. Unilateral facial injection of botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety‐like behaviors through inhibition of TLR2‐mediated neuroinflammation in mice. J Headache Pain. 2021;22(1):38.
Zychowska M, Rojewska E, Makuch W, Luvisetto S, Pavone F, Marinelli S, et al. Participation of pro‐ and anti‐nociceptive interleukins in botulinum toxin A‐induced analgesia in a rat model of neuropathic pain. Eur J Pharmacol. 2016;791:377–388.
Park J, Park HJ. Botulinum toxin for the treatment of neuropathic pain. Toxins (Basel). 2017;9(9):260.
Oh HM, Chung ME. Botulinum toxin for neuropathic pain: A review of the literature. Toxins (Basel). 2015;7(8):3127–3154.
Lippi L, de Sire A, Folli A, D'Abrosca F, Grana E, Baricich A, et al. Multidimensional effectiveness of botulinum toxin in neuropathic pain: A systematic review of randomized clinical trials. Toxins (Basel). 2022;14(5):308.
Wang C, Zhang Q, Wang R, Xu L. Botulinum toxin type A for diabetic peripheral neuropathy pain: A systematic review and meta‐analysis. J Pain Res. 2021;14:3855–3863.
Datta Gupta A, Edwards S, Smith J, Snow J, Visvanathan R, Tucker G, et al. A systematic review and meta‐analysis of efficacy of botulinum toxin A for neuropathic pain. Toxins (Basel). 2022;14(1):36.
Maslenikov N, Tsukarzi E, Mosolov S. Repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression in schizophrenia patients. Ann General Psychiatry. 2008;7(1):S312.
Leung A, Donohue M, Xu R, Lee R, Lefaucheur JP, Khedr EM, et al. rTMS for suppressing neuropathic pain: a meta‐analysis. J Pain. 2009;10(12):1205–1216.
Toledo RS, Stein DJ, Sanches PRS, da Silva LS, Medeiros HR, Fregni F, et al. rTMS induces analgesia and modulates neuroinflammation and neuroplasticity in neuropathic pain model rats. Brain Res. 2021;1762:147427.
Hu Y, Zhu Y, Wen X, Zeng F, Feng Y, Xu Z, et al. Repetitive transcranial magnetic stimulation regulates neuroinflammation, relieves hyperalgesia and reverses despair‐like behaviour in chronic constriction injury rats. Eur J Neurosci. 2022;56(6):4930–4947.
Henter ID, de Sousa RT, Zarate CA. Glutamatergic modulators in depression. Harv Rev Psychiatry. 2018;26(6):307–319.
Gatzinsky K, Bergh C, Liljegren A, Silander H, Samuelsson J, Svanberg T, et al. Repetitive transcranial magnetic stimulation of the primary motor cortex in management of chronic neuropathic pain: a systematic review. Scand J Pain. 2021;21(1):8–21.
Jiang X, Yan W, Wan R, Lin Y, Zhu X, Song G, et al. Effects of repetitive transcranial magnetic stimulation on neuropathic pain: A systematic review and meta‐analysis. Neurosci Biobehav Rev. 2022;132:130–141.
Li X, Lu T, Yu H, Shen J, Chen Z, Yang X, et al. Repetitive transcranial magnetic stimulation for neuropathic pain and neuropsychiatric symptoms in traumatic brain injury: a systematic review and meta‐analysis. Neural Plast. 2022;2022:2036736.
Gayduk AJ, Shishkovskaia TI, Cumming P, Koutsomitros T, Sack AT, Vlasov YV, et al. Association between neuropathic pain and depression: focusing on the transcranial magnetic stimulation as a promising treatment approach. Psychiatr Danub. 2022;34(Suppl 8):105–111.
Gao C, Zhu Q, Gao Z, Zhao J, Jia M, Li T. Can noninvasive brain stimulation improve pain and depressive symptoms in patients with neuropathic pain? A systematic review and meta‐analysis. J Pain Symptom Manag. 2022;64(4):e203–e215.
Hsu JH, Daskalakis ZJ, Blumberger DM. An update on repetitive transcranial magnetic stimulation for the treatment of Co‐morbid pain and depressive symptoms. Curr Pain Headache Rep. 2018;22(7):51.
Dubin M. Imaging TMS: antidepressant mechanisms and treatment optimization. Int Rev Psychiatry. 2017;29(2):89–97.
Peng Z, Zhou C, Xue S, Bai J, Yu S, Li X, et al. Mechanism of repetitive transcranial magnetic stimulation for depression. Shanghai Arch Psychiatry. 2018;30(2):84–92.
Kenney‐Jung DL, Blacker CJ, Camsari DD, Lee JC, Lewis CP. Transcranial direct current stimulation: mechanisms and psychiatric applications. Child Adolesc Psychiatr Clin N Am. 2019;28(1):53–60.
Stagg CJ, Nitsche MA. Physiological basis of transcranial direct current stimulation. Neuroscientist. 2011;17(1):37–53.
Santos DS, Lopes BC, Medeiros LF, Assumpção JAF, de Souza A, Salvi AA, et al. Transcranial direct current stimulation (tDCS) induces analgesia in rats with neuropathic pain and alcohol abstinence. Neurochem Res. 2020;45(11):2653–2663.
Lopes BC, Medeiros LF, Silva de Souza V, Cioato SG, Medeiros HR, Regner GG, et al. Transcranial direct current stimulation combined with exercise modulates the inflammatory profile and hyperalgesic response in rats subjected to a neuropathic pain model: long‐term effects. Brain Stimul. 2020;13(3):774–782.
Gan Z, Li H, Naser PV, Oswald MJ, Kuner R. Suppression of neuropathic pain and comorbidities by recurrent cycles of repetitive transcranial direct current motor cortex stimulation in mice. Sci Rep. 2021;11(1):9735.
Santos DS, Stein DJ, Medeiros HR, dos Santos Pereira F, de Macedo IC, Fregni F, et al. Transcranial direct current stimulation alters anxious‐like behavior and neural parameters in rats with chronic pain exposed to alcohol. J Psychiatr Res. 2021;144:369–377.
Akcay G, Nemutlu Samur D, Derin N. Transcranial direct current stimulation alleviates nociceptive behavior in male rats with neuropathic pain by regulating oxidative stress and reducing neuroinflammation. J Neurosci Res. 2023;101(9):1457–1470.
Yoon EJ, Kim YK, Kim HR, Kim SE, Lee Y, Shin HI. Transcranial direct current stimulation to lessen neuropathic pain after spinal cord injury: a mechanistic PET study. Neurorehabil Neural Repair. 2014;28(3):250–259.
Ngernyam N, Jensen MP, Arayawichanon P, Auvichayapat N, Tiamkao S, Janjarasjitt S, et al. The effects of transcranial direct current stimulation in patients with neuropathic pain from spinal cord injury. Clin Neurophysiol. 2015;126(2):382–390.
Thibaut A, Carvalho S, Morse LR, Zafonte R, Fregni F. Delayed pain decrease following M1 tDCS in spinal cord injury: a randomized controlled clinical trial. Neurosci Lett. 2017;658:19–26.
Young J, Zoghi M, Khan F, Galea MP. The effect of transcranial direct current stimulation on chronic neuropathic pain in patients with multiple sclerosis: randomized controlled trial. Pain Med. 2020;21(12):3451–3457.
Li L, Huang H, Yu Y, Jia Y, Liu Z, Shi X, et al. Non‐invasive brain stimulation for neuropathic pain after spinal cord injury: a systematic review and network meta‐analysis. Front Neurosci. 2022;15:800560.
Berlim MT, Van den Eynde F, Daskalakis ZJ. Clinical utility of transcranial direct current stimulation (tDCS) for treating major depression: a systematic review and meta‐analysis of randomized, double‐blind and sham‐controlled trials. J Psychiatr Res. 2013;47(1):1–7.
Zhou Q, Yu C, Yu H, Zhang Y, Liu Z, Hu Z, et al. The effects of repeated transcranial direct current stimulation on sleep quality and depression symptoms in patients with major depression and insomnia. Sleep Med. 2020;70:17–26.
Zhang R, Lam CLM, Peng X, Zhang D, Zhang C, Huang R, et al. Efficacy and acceptability of transcranial direct current stimulation for treating depression: a meta‐analysis of randomized controlled trials. Neurosci Biobehav Rev. 2021;126:481–490.
Fregni F, El‐Hagrassy MM, Pacheco‐Barrios K, Carvalho S, Leite J, Simis M, et al. Evidence‐based guidelines and secondary meta‐analysis for the use of transcranial direct current stimulation in neurological and psychiatric disorders. Int J Neuropsychopharmacol. 2021;24(4):256–313.
Heimrath K, Brechmann A, Blobel‐Lüer R, Stadler J, Budinger E, Zaehle T. Transcranial direct current stimulation (tDCS) over the auditory cortex modulates GABA and glutamate: a 7 T MR‐spectroscopy study. Sci Rep. 2020;10(1):20111.
Liebert A, Capon W, Pang V, Vila D, Bicknell B, McLachlan C, et al. Photophysical mechanisms of photobiomodulation therapy as precision medicine. Biomedicine. 2023;11(2):237.
Karu T. Primary and secondary mechanisms of action of visible to near‐IR radiation on cells. J Photochem Photobiol B. 1999;49(1):1–17.
Laakso EL, Cabot PJ. Nociceptive scores and endorphin‐containing cells reduced by low‐level laser therapy (LLLT) in inflamed paws of Wistar rat. Photomed Laser Surg. 2005;23(1):32–35.
Janzadeh A, Nasirinezhad F, Masoumipoor M, Jameie SB, Hayat P. Photobiomodulation therapy reduces apoptotic factors and increases glutathione levels in a neuropathic pain model. Lasers Med Sci. 2016;31(9):1863–1869.
Micheli L, Cialdai F, Pacini A, Branca JJV, Morbidelli L, Ciccone V, et al. Effect of NIR laser therapy by MLS‐MiS source against neuropathic pain in rats: in vivo and ex vivo analysis. Sci Rep. 2019;9(1):9297.
Janzadeh A, Sarveazad A, Hamblin MR, Teheripak G, Kookli K, Nasirinezhad F. The effect of chondroitinase ABC and photobiomodulation therapy on neuropathic pain after spinal cord injury in adult male rats. Physiol Behav. 2020;227:113141.
de Andrade ALM, Bossini PS, do Canto De Souza ALM, Sanchez AD, Parizotto NA. Effect of photobiomodulation therapy (808 nm) in the control of neuropathic pain in mice. Lasers Med Sci. 2017;32(4):865–872.
Masoumipoor M, Jameie SB, Janzadeh A, Nasirinezhad F, Soleimani M, Kerdary M. Effects of 660‐ and 980‐nm low‐level laser therapy on neuropathic pain relief following chronic constriction injury in rat sciatic nerve. Lasers Med Sci. 2014;29(5):1593–1598.
Oliveira ME, Santos FM, Bonifácio RP, Freitas MF, Martins DO, Chacur M. Low level laser therapy alters satellite glial cell expression and reverses nociceptive behavior in rats with neuropathic pain. Photochem Photobiol Sci. 2017;16(4):547–554.
de Oliveira ME, Da Silva JT, Brioschi ML, Chacur M. Effects of photobiomodulation therapy on neuropathic pain in rats: evaluation of nociceptive mediators and infrared thermography. Lasers Med Sci. 2021;36(7):1461–1467.
Vieira WF, de Magalhães SF, Farias FH, de Thomaz AA, Parada CA. Raman spectroscopy of dorsal root ganglia from streptozotocin‐induced diabetic neuropathic rats submitted to photobiomodulation therapy. J Biophotonics. 2019;12(11):e201900135.
Vieira WF, Malange KF, de Magalhães SF, Lemes JBP, dos Santos GG, Nishijima CM, et al. Anti‐hyperalgesic effects of photobiomodulation therapy (904 nm) on streptozotocin‐induced diabetic neuropathy imply MAPK pathway and calcium dynamics modulation. Sci Rep. 2022;12(1):16730.
Yang L, Wu C, Tucker L, Dong Y, Li Y, Xu P, et al. Photobiomodulation therapy attenuates anxious‐depressive‐like behavior in the TgF344 rat model. J Alzheimers Dis. 2021;83(4):1415–1429.
Zhang D, Shen Q, Wu X, Xing D. Photobiomodulation therapy ameliorates glutamatergic dysfunction in mice with chronic unpredictable mild stress‐induced depression. Oxidative Med Cell Longev. 2021;2021:6678276.
Xu Z, Guo X, Yang Y, Tucker D, Lu Y, Xin N, et al. Low‐level laser irradiation improves depression‐like behaviors in mice. Mol Neurobiol. 2017;54(6):4551–4559.
Eshaghi E, Sadigh‐Eteghad S, Mohaddes G, Rasta SH. Transcranial photobiomodulation prevents anxiety and depression via changing serotonin and nitric oxide levels in brain of depression model mice: a study of three different doses of 810 nm laser. Lasers Surg Med. 2019;51(7):634–642.
Anju M, Ummer VS, Maiya AG, Hande M. Low level laser therapy for the patients with painful diabetic peripheral neuropathy – a systematic review. Diabetes Metab Syndr. 2019;13(4):2667–2670.
de Andrade ALM, Bossini PS, Parizotto NA. Use of low level laser therapy to control neuropathic pain: a systematic review. J Photochem Photobiol B. 2016;164:36–42.
Khamseh ME, Kazemikho N, Aghili R, Forough B, Lajevardi M, Hashem Dabaghian F, et al. Diabetic distal symmetric polyneuropathy: effect of low‐intensity laser therapy. Lasers Med Sci. 2011;26(6):831–835.
Dompe C, Moncrieff L, Matys J, Grzech‐Leśniak K, Kocherova I, Bryja A, et al. Photobiomodulation‐underlying mechanism and clinical applications. J Clin Med. 2020;9(6):1724.
Hopkins JT, McLoda TA, Seegmiller JG, David Baxter G. Low‐level laser therapy facilitates superficial wound healing in humans: a triple‐blind, sham‐controlled study. J Athl Train. 2004;39(3):223–229.
Oron A, Oron U, Streeter J, Taboada LD, Alexandrovich A, Trembovler V, et al. Low‐level laser therapy applied transcranially to mice following traumatic brain injury significantly reduces long‐term neurological deficits. J Neurotrauma. 2007;24(4):651–656.
Chow RT, David MA, Armati PJ. 830 nm laser irradiation induces varicosity formation, reduces mitochondrial membrane potential and blocks fast axonal flow in small and medium diameter rat dorsal root ganglion neurons: implications for the analgesic effects of 830 nm laser. J Peripher Nerv Syst. 2007;12(1):28–39.
Yeh SW, Hong CH, Shih MC, Tam KW, Huang YH, Kuan YC. Low‐level laser therapy for fibromyalgia: a systematic review and meta‐analysis. Pain Physician. 2019;22(3):241–254.
Cassano P, Cusin C, Mischoulon D, Hamblin MR, de Taboada L, Pisoni A, et al. Near‐infrared transcranial radiation for major depressive disorder: proof of concept study. Psychiatry J. 2015;2015:352979.
Maiello M, Losiewicz OM, Bui E, Spera V, Hamblin MR, Marques L, et al. Transcranial photobiomodulation with near‐infrared light for generalized anxiety disorder: a pilot study. Photobiomodul Photomed Laser Surg. 2019;37(10):644–650.
Kerppers FK, Dos Santos KMMG, Cordeiro MER, da Silva Pereira MC, Barbosa D, Pezzini AA, et al. Study of transcranial photobiomodulation at 945‐nm wavelength: anxiety and depression. Lasers Med Sci. 2020;35(9):1945–1954.
Zhao ZQ. Neural mechanism underlying acupuncture analgesia. Prog Neurobiol. 2008;85(4):355–375.
Li Y, Yin C, Li X, Liu B, Wang J, Zheng X, et al. Electroacupuncture alleviates paclitaxel‐induced peripheral neuropathic pain in rats via suppressing TLR4 signaling and TRPV1 upregulation in sensory neurons. Int J Mol Sci. 2019;20(23):5917.
Li Q, Yue N, Liu SB, Wang ZF, Mi WL, Jiang JW, et al. Effects of chronic electroacupuncture on depression‐ and anxiety‐like behaviors in rats with chronic neuropathic pain. Evid Based Complement Alternat Med. 2014;2014:158987.
Zhang XH, Feng CC, Pei LJ, Zhang YN, Chen L, Wei XQ, et al. Electroacupuncture attenuates neuropathic pain and comorbid negative behavior: the involvement of the dopamine system in the amygdala. Front Neurosci. 2021;15:657507.
Cong W, Peng Y, Meng B, Jia X, Jin Z. The effect of electroacupuncture on regulating pain and depression‐like behaviors induced by chronic neuropathic pain. Ann Palliat Med. 2021;10(1):104–113.
Lee S, Lee CS, Moon JY, Song HG, Yoo Y, Kim J, et al. Electroacupuncture may improve burning and electric shock‐like neuropathic pain: A prospective exploratory pilot study. J Altern Complement Med. 2020;26(12):1136–1143.
Meyer‐Hamme G, Friedemann T, Greten J, Gerloff C, Schroeder S. Electrophysiologically verified effects of acupuncture on diabetic peripheral neuropathy in type 2 diabetes: the randomized, partially double‐blinded, controlled ACUDIN trial. J Diabetes. 2021;13(6):469–481.
Martin G, Nie Z, Siggins GR. μ‐Opioid receptors modulate NMDA receptor‐mediated responses in nucleus accumbens neurons. J Neurosci. 1997;17(1):11–22.
Smith CA, Hay PP, Macpherson H. Acupuncture for depression. Cochrane Database Syst Rev. 2010;(1):CD004046.
Fisher E, Law E, Dudeney J, Eccleston C, Palermo TM. Psychological therapies (remotely delivered) for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2019;4(4):CD011118.
van de Wetering EJ, Lemmens KMM, Nieboer AP, Huijsman R. Cognitive and behavioral interventions for the management of chronic neuropathic pain in adults – a systematic review. Eur J Pain. 2010;14(7):670–681.
Eccleston C, Hearn L, de C Williams AC. Psychological therapies for the management of chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2015;2015(10):CD011259.
Hall J, Kellett S, Berrios R, Bains MK, Scott S. Efficacy of cognitive behavioral therapy for generalized anxiety disorder in older adults: systematic review, meta‐analysis, and meta‐regression. Am J Geriatr Psychiatry. 2016;24(11):1063–1073.
Jandaghi G, Firoozi M, Zia‐Tohidi A. Psychological interventions for depression and anxiety: a systematic review and meta‐analysis of Iranian chronic pain trials. Health Promot Perspect. 2020;10(3):180–191.